NASDAQ · SLP
Healthcare · Medical - Healthcare Information Services
$18.43
Up+$0.02 (+0.11%)
Updated Sep 17, 2026, 8:45 AM
SID Score
6.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
SLP closed at $18.43 after 20 trading sessions, up 0.33% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $18.41 | $18.44 | $18.40 | $18.43 | 166.52K |
| Sep 15, 2026 | $18.42 | $18.42 | $18.40 | $18.41 | 116.38K |
| Sep 14, 2026 | $18.42 | $18.43 | $18.41 | $18.42 | 249.37K |
| Sep 11, 2026 | $18.42 | $18.43 | $18.42 | $18.42 | 133.57K |
| Sep 10, 2026 | $18.42 | $18.43 | $18.42 | $18.42 | 187.88K |
| Sep 9, 2026 | $18.44 | $18.44 | $18.42 | $18.42 | 181.15K |
| Sep 8, 2026 | $18.43 | $18.44 | $18.42 | $18.42 | 156.75K |
| Sep 4, 2026 | $18.44 | $18.45 | $18.42 | $18.43 | 79.05K |
| Sep 3, 2026 | $18.45 | $18.46 | $18.42 | $18.42 | 426.69K |
| Sep 2, 2026 | $18.42 | $18.45 | $18.41 | $18.43 | 257.09K |
| Sep 1, 2026 | $18.39 | $18.42 | $18.39 | $18.42 | 173.83K |
| Aug 31, 2026 | $18.39 | $18.41 | $18.38 | $18.40 | 171.07K |
| Aug 28, 2026 | $18.42 | $18.42 | $18.39 | $18.39 | 139.11K |
| Aug 27, 2026 | $18.40 | $18.42 | $18.40 | $18.42 | 157.2K |
| Aug 26, 2026 | $18.39 | $18.41 | $18.39 | $18.41 | 137.6K |
| Aug 25, 2026 | $18.40 | $18.40 | $18.38 | $18.39 | 89.12K |
| Aug 24, 2026 | $18.38 | $18.41 | $18.38 | $18.40 | 169.86K |
| Aug 21, 2026 | $18.41 | $18.41 | $18.37 | $18.40 | 116.56K |
| Aug 20, 2026 | $18.37 | $18.40 | $18.37 | $18.38 | 134.91K |
| Aug 19, 2026 | $18.40 | $18.41 | $18.36 | $18.37 | 291.04K |
The latest Smart Investors Daily articles mentioning SLP.
SLP research
Company profile and research snapshot.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 17, 2026 | William Blair | Market Perform | — |
| Apr 10, 2026 | TD Cowen | Hold | — |
| Jan 8, 2026 | TD Cowen | Hold | — |
| Dec 18, 2025 | BTIG | Neutral | — |
| Sep 30, 2025 | TD Cowen | Hold | — |
No generated briefing is available yet.
Benzinga · Aug 13, 2026
Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, announced the
SeekingAlpha · Jul 19, 2026
Simulations Plus posts 7% revenue growth as Altaris targets a $375M buyout at $18.50/share. Click for more on SLP stock.
SeekingAlpha · Jul 10, 2026
2026-07-10. The following slide deck was published by Simulations Plus, Inc.
Benzinga · Jul 10, 2026
Simulations Plus (NASDAQ:SLP) affirms FY2026 Adj EPS guidance from $0.75-$0.85 to $0.75-$0.85 vs $0.42 analyst estimate. Affirms FY2026 sales outlook from $79.000 million-$82.000 million to $79.000 million-$82.000
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SLP.
